Abstract
BackgroundImmunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases.ObjectivesTo study the relation between clinical response, adalimumab levels and anti-drug antibodies (ADA) in ankylosing spondylitis (AS) patients.MethodsObservational...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
